Using gender specific thresholds for abnormalities in cardiac troponin I, the rate of injury among women increased by 42%. This did not translate into improved management of women, who remained about half as likely to undergo revascularization, receive dual antiplatet therapy, or undergo other interventions.
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Coronary Disease - PCI
October 15, 2019
September 14, 2019
This study reports ten year outcomes of the STICH trial. Comparing CABG to medical therapy groups, the authors note that CABG reduced all cause, cardiovascular, and heart failure hospitalizations. This included time-to-first and recurrent events. This was due to fewer total cardiovascular hospitalizations, the majority due to heart failure.
September 3, 2019
Remote ischemic preconditioning did not influence 12-month survival or readmission rates in a randomized trial involving more than 5,400 patients undergoing percutaneous coronary intervention after ST-segment elevation MI.
September 1, 2019
Interesting viewpoint of a cardiologist on low-SYNTAX subjects.
August 29, 2019
An interesting meta-analysis discouraging perhaps the use of this KATP modulator, especially after surgical revascularization where optimization of serum potassium is generally sought.
August 26, 2019
Using data from more than 3.3 million patients in the NCDR CathPCI Registry, researchers used machine learning to develop an algorithm that predicts post-PCI major bleeding with a C-statistic of 0.82.
July 1, 2019
This video demonstrates working as a team to improve the outcomes of people who arrest or have an acute emergency in the catheterization laboratory.
June 27, 2019
An interesting small British-led randomized controlled trial on modern imaging of coronary atheroma.
May 15, 2019
An interesting metanalysis, especially:
The ad hoc results of off-pump surgery.
The mean number of silent brain infarcts per patient was significantly higher in the transcatheter aortic valve implantation group (4.58 ± 2.09) compared with the aortic valve replacement group (2.16 ± 1.62, P=0.03).
May 14, 2019
Ticagrelor (Brilinta), an oral P2Y12 inhibitor, is an agent used in combination with aspirin for dual antiplatelet therapy after coronary interventions. It's antiplatelet function cannot be reversed by platelet transfusion.